Mostrar el registro sencillo del documento

Estudio de eventos adversos asociados al consumo de diferentes antidiabéticos en Colombia entre 2013 – 2018

dc.rights.licenseAtribución-NoComercial 4.0 Internacional
dc.contributor.advisorVaca Gonzales, Claudia Patricia
dc.contributor.advisorde las Salas Martínez, Roxana Patricia
dc.contributor.authorPino Muñoz, Arley
dc.date.accessioned2020-10-19T17:16:21Z
dc.date.available2020-10-19T17:16:21Z
dc.date.issued2019-08-19
dc.identifier.urihttps://repositorio.unal.edu.co/handle/unal/78545
dc.description.abstractObjetivo: Realizar un estudio de eventos adversos (EA) en relación con el consumo de diferentes antidiabéticos en el periodo 2013-2018. Métodos: estudio de corte trasversal retrospectivo utilizando las bases nacionales de ventas de medicamentos (SISMED) y los reportes de Eventos Adversos (INVIMA) de los actores de la red Nacional de Farmacovigilancia. Se calculó la Dosis Diaria Definida (DDD) por 1000 hab./día, número de reportes de EA, SOC afectado, seriedad y evaluación de causalidad. Se identificaron señales con el método de razón de notificación proporcional (PRR). Se comparó el consumo expresado en DDD por 1000 hab./día con el número de EA notificados. Resultados: Se revisaron 1.066 registros de ventas y 1739 reportes de EA. De acuerdo a los datos registrados los iDPP-4 son los más consumidos (DDD= 3,24; EA=252), seguidos por los iSGLT-2 (DDD=0,94; EA=490) y los ARGLP-1 (DDD=0,385; EA=815). El medicamento más consumido fue sitagliptina. Exenatida fue el medicamento con el mayor número de notificaciones. El análisis de desproporcionalidad permitió identificar 8 señales: pancreatitis/vildagliptina (PRR=7,47 IC95%=1,66-33,57), amputaciones/liraglutida (PRR=11,03 IC95%=1,15-105,67), neoplasia-dapagliflozina y empagliflozina (PRR= 18,20 IC95%=3,84-86,28 y PRR=5,07 IC95%=1,04-24,08), urosepsis-empagliflozina (PRR=4,75 IC95%=1,78-12,71) extrasístoles supraventriculares-vildagliptina (PRR=94,85 IC95%=10,75-836,45), hiperglucemia-dapagliflozina (PRR=36,40 IC95%=6,33-209,44), infartos agudos al miocardio-exenatida y lixesenatida (PRR=6,70 IC95%=2,30-19,47 y PRR=11,05 IC95%= 76,22) y dolor abdominal-sitagliptina (PRR= 11,86 IC95%=3,03-46,33). Conclusiones: No parece existir una relación entre las variables consumo -población expuesta- y número de notificaciones, que confirma la infra notificación de los sistemas de farmacovigilancia, sin embargo los iSGLT2 parecen presentar un crecimiento proporcional al incremento de notificaciones en función al consumo.
dc.description.abstractAims: To appraise the notified adverse events (AE) survey related with the drug consume of antidiabetic drugs between 2013-2018. Methods: A transverse cross-sectional study was planned using the national database of sales of medicines (SISMED) and AE (INVIMA). Reports related to the research molecules were included. The variables to be evaluated included: DDD per 1000 hab-days, number of AE reports, affected SOC, seriousness and causality evaluation. The proportional reporting ratio method (PRR) was used to evaluate the existence of signals. Consumption expressed as DDD per 1000 population days was compared to the number of reported AE. Results: 1,066 sales registers and 1,739 AE reports were reviewed. According to the data, DPP-4 inhibitors are most consumed drug (DDD= 3,24; AE=252), followed by SGLT-2 inhibitors (DDD=0,94; AE=490) and finally GLP-1 RA (DDD=0,385; AE=815). The most consumed drug was sitagliptin. Exenatide was the drug with the highest number of notifications. The proportional reporting ratio allowed to identify 8 signals: pancreatitis-vildagliptin (PRR=7,47 CI95%=1,66-33,57), amputations-liraglutide (PRR=11,03 CI95%=1,15-105,67), neoplasia-dapagliflozin and empagliflozin (PRR= 18,20 CI95%=3,84-86,28 and PRR=5,07 CI95%=1,04-24,08), urosepsis-empagliflozin (PRR=4,75 CI95%=1,78-12,71) supraventricular extrasystole-Vildagliptin (PRR=94,85 CI95%=10,75-836,45), Hyperglycemia-dapagliflozin (PRR=36,40 CI95%=6,33-209,44), Acute myocardial infarctions-exenatide and lixisenatide (PRR=6,70 CI95%=2,30-19,47 and PRR=11,05 CI95%= 76,22) and abdominal pain -sitagliptina (PRR= 11,86 CI95%=3,03-46,33). Conclusions: It was found that there were not a clear behavior that related both variables as it was expected (More exposed population, they will consume more, more notifications are going to be submitted), nevertheless SGLT2 inhibitors seem to have a proportional growth of notifications of AE in function to drug consume.
dc.format.extent101
dc.format.mimetypeapplication/pdf
dc.language.isospa
dc.rightsDerechos reservados - Universidad Nacional de Colombia
dc.rights.urihttp://creativecommons.org/licenses/by-nc/4.0/
dc.subject.ddc610 - Medicina y salud::615 - Farmacología y terapéutica
dc.titleEstudio de eventos adversos asociados al consumo de diferentes antidiabéticos en Colombia entre 2013 – 2018
dc.title.alternativeStudy of adverse events related with the consume of diferent antidiabetic drugs in Colombia between 2013-2018
dc.typeOtro
dc.rights.spaAcceso abierto
dc.description.additionalLínea de Investigación: Farmacoepidemiología
dc.type.driverinfo:eu-repo/semantics/other
dc.type.versioninfo:eu-repo/semantics/acceptedVersion
dc.publisher.programBogotá - Ciencias - Maestría en Ciencias - Farmacología
dc.contributor.researchgroupRAM (Red para el uso Adecuado de Medicamentos)
dc.description.degreelevelMaestría
dc.publisher.departmentDepartamento de Farmacia
dc.publisher.branchUniversidad Nacional de Colombia - Sede Bogotá
dc.relation.referencesAmerican Diabetes Association. (2019a). Classification and diagnosis of diabetes: Standards of medical care in diabetes. Diabetes Care, 42(January), S13–S28. https://doi.org/10.2337/dc19-S002
dc.relation.referencesAmerican Diabetes Association. (2019b). Introduction: Standards of Medical Care in Diabetes 2019. En Diabetes Care (Vol. 42). https://doi.org/10.2337/dc19-Sint01
dc.relation.referencesAmerican Diabetes Association. (2019c). Pharmacologic approaches to glycemie treatment: Standards of medical care in diabetes-2018. Diabetes Care, 42(Supplement 1), S90-102. https://doi.org/10.6314/JIMT.201804_29(2).06
dc.relation.referencesArnaud, M., Bezin, J., Bégaud, B., Pariente, A., & Salvo, F. (2017). Trends in the incidence of use of noninsulin glucose-lowering drugs between 2006 and 2013 in France. Fundamental & Clinical Pharmacology, 31(1), 663–675. https://doi.org/10.1111/fcp.12298
dc.relation.referencesBekiari, E., Rizava, C., Athanasiadou, E., Papatheodorou, K., Liakos, A., Karagiannis, T., … Tsapas, A. (2016). Systematic review and meta-analysis of vildagliptin for treatment of type 2 diabetes. Endocrine, 52(3), 458–480. https://doi.org/10.1007/s12020-015-0841-1
dc.relation.referencesButler, A. E., Campbell-Thompson, M., Gurlo, T., Dawson, D. W., Atkinson, M., & Butler, P. C. (2013). Marked Expansion of Exocrine and Endocrine Pancreas With Incretin Therapy in Humans With Increased Exocrine Pancreas Dysplasia and the Potential for Glucagon-Producing Neuroendocrine Tumors. Diabetes, 62(7), 2595–2604. https://doi.org/10.2337/db12-1686
dc.relation.referencesCai, L., Cai, Y., Lu, Z. J., Zhang, Y., & Liu, P. (2012). The efficacy and safety of vildagliptin in patients with type 2 diabetes: a meta-analysis of randomized clinical trials. Journal of Clinical Pharmacy and Therapeutics, 37(4), 386–398. https://doi.org/10.1111/j.1365-2710.2011.01323.x
dc.relation.referencesCaster, O., Juhlin, K., Watson, S., & Norén, G. N. (2014). Improved Statistical Signal Detection in Pharmacovigilance by Combining Multiple Strength-of-Evidence Aspects in vigiRank. Drug Safety, 37(8), 617–628. https://doi.org/10.1007/s40264-014-0204-5
dc.relation.referencesChesterman, T., & Thynne, T. R. (2020). Harms and benefits fo sodium-glucose co-transporter 2 inhibitors. Australian Prescriber, 43(5), 168–171. https://doi.org/10.18773/austprescr.2020.049
dc.relation.referencesClemens, K. K., Shariff, S., Liu, K., Hramiak, I., Mahon, J. L., McArthur, E., & Garg, A. X. (2015). Trends in antihyperglycemic medication prescriptions and hypoglycemia in older adults: 2002-2013. PLoS ONE, 10(9), 2002–2013. https://doi.org/10.1371/journal.pone.0137596
dc.relation.referencesCongreso de la Republica. Ley estatutaria 1266. , (2008).
dc.relation.referencesCongreso de la Republica. Ley estatutaria 1581. , (2012).
dc.relation.referencesConsejo de Organizaciones Internacionales de las Ciencias Médicas (CIOMS), & OMS. (2017). Pautas CIOMS 2017. En Pautas éticas internacionales para la investigación biomédica en seres humanos. Recuperado de https://cioms.ch/wp-content/uploads/2017/12/CIOMS-EthicalGuideline_SP_INTERIOR-FINAL.pdf
dc.relation.referencesDel Olmo-Garcia, M. I., & Merino-Torres, J. F. (2018). GLP-1 receptor agonists and cardiovascular disease in patients with type 2 diabetes. Journal of Diabetes Research, 2018. https://doi.org/10.1155/2018/4020492
dc.relation.referencesDesai, Nihar; Shrank, William; Fischer, Michael; Avorn, J. et. al. (2012). Patterns of medication initiation in newly diagnosed diabetes mellitus: Quality and cost implications. American Journal of Medicine, 125(10), S1. https://doi.org/10.1016/j.amjmed.2012.05.001
dc.relation.referencesDhatariya, K., Bain, S. C., Buse, J. B., Simpson, R., Tarnow, L., Kaltoft, M. S., … Pratley, R. E. (2018). The Impact of Liraglutide on Diabetes-Related Foot Ulceration and Associated Complications in Patients With Type 2 Diabetes at High Risk for Cardiovascular Events: Results From the LEADER Trial. Diabetes Care, 41(10), 2229–2235. https://doi.org/10.2337/dc18-1094
dc.relation.referencesDicembrini, I., Montereggi, C., Nreu, B., Mannucci, E., & Monami, M. (2020). Pancreatitis and pancreatic cancer in patientes treated with Dipeptidyl Peptidase-4 inhibitors: An extensive and updated meta-analysis of randomized controlled trials. Diabetes Research and Clinical Practice, 159, 107981. https://doi.org/10.1016/j.diabres.2019.107981
dc.relation.referencesEMA. (s/f). Jardiance: EPAR-Risk Managent Plan Summary. Recuperado el 22 de junio de 2020, de www.EMA.europea.eu website: https://www.ema.europa.eu/en/medicines/human/EPAR/jardiance
dc.relation.referencesEMA. (2013). Investigation into GLP-1-based diabetes therapies concluded.
dc.relation.referencesGarber, A. J., Abrahamson, M. J., Barzilay, J. I., Blonde, L., Bloomgarden, Z. T., Bush, M. A., … Umpierrez, G. E. (2018). Consensus Statement By the American Association of Clinical Endocrinologists and American College of Endocrinology on the Comprehensive Type 2 Diabetes Management Algorithm – 2018 Executive Summary. Endocrine Practice, 24(1), 91–120. https://doi.org/10.4158/ep161682.cs
dc.relation.referencesGaviria-Mendoza, A., Sánchez-Duque, J. A., Medina-Morales, D. A., & Machado-Alba, J. E. (2018). Prescription patterns and costs of antidiabetic medications in a large group of patients. Primary Care Diabetes, 12(2), 184–191. https://doi.org/10.1016/j.pcd.2017.11.002
dc.relation.referencesGirgis, C., & Champion, B. (2011). Vildagliptin-Induced Acute Pancreatitis. Endocrine Practice, 17(3), e48–e50. https://doi.org/10.4158/EP10383.CR
dc.relation.referencesGreen, J. B., Bethel, M. A., Armstrong, P. W., Buse, J. B., Engel, S. S., Garg, J., … Holman, R. R. (2015). Effect of sitagliptin on cardiovascular outcomes in type 2 diabetes. New England Journal of Medicine, 373(3), 232–242. https://doi.org/10.1056/NEJMoa1501352
dc.relation.referencesHankó, B., Tukarcs, É., Kumli, P., & Vincze, Z. (2005). Antidiabetic drug utilization in Hungary. Pharmacy World and Science, 27(3), 263–265. https://doi.org/10.1007/s11096-004-5804-1
dc.relation.referencesHolman, R. R., Bethel, M. A., Mentz, R. J., Thompson, V. P., Lokhnygina, Y., Buse, J. B., … Hernandez, A. F. (2017). Effects of Once-Weekly Exenatide on Cardiovascular Outcomes in Type 2 Diabetes. New England Journal of Medicine, 377(13), 1228–1239. https://doi.org/10.1056/NEJMoa1612917
dc.relation.referencesHtike, Z. Z., Zaccardi, F., Papamargaritis, D., Webb, D. R., Khunti, K., & Davies, M. J. (2017). Efficacy and safety of glucagon-like peptide-1 receptor agonists in type 2 diabetes: A systematic review and mixed-treatment comparison analysis. Diabetes, Obesity and Metabolism, 19(4), 524–536. https://doi.org/10.1111/dom.12849
dc.relation.referencesIBM Watson Health. (2019). IBM Micromedex® (electronic version). Recuperado el 9 de junio de 2019, de https://www-micromedexsolutions-com.ezproxy.unal.edu.co
dc.relation.referencesINVIMA. (s/f). Gestión de señales, programa nacional de farmacovigilanica medicamentos medicamentos biológicos y de sintesis química. Recuperado el 1 de septiembre de 2020, de https://www.invima.gov.co/web/guest/biologicos-y-de-sintesis-quimica
dc.relation.referencesINVIMA. Resolución 2004009455. , (2004).
dc.relation.referencesINVIMA. (2019). Instituto Nacional de Vigilancia de medicamentos y alimentos. Recuperado el 22 de junio de 2019, de https://www.invima.gov.co/
dc.relation.referencesKannan, Arshad, & Kumar, S. (2011). A study on drug utilization of oral hypoglycemic agents in type-2 diabetic patients. Asian Journal of Pharmaceutical and Clinical Research, 4(4), 60–64.
dc.relation.referencesKaragiannis, T., Boura, P., & Tsapas, A. (2014). Safety of dipeptidyl peptidase 4 inhibitors: a perspective review. Therapeutic Advances in Drug Safety, 5(3), 138–146. https://doi.org/10.1177/2042098614523031
dc.relation.referencesKing, J., McAdam-Marx, C., McCaleb, R., Davis, D., Bemberg, G. B., & Johnson, J. T. (2019). Cost and utilization outcomes after exclusion of dipeptidyl peptidase-4 inhibitors and other diabetes drug category changes in a self-funded, state employee managed care plan. Journal of Managed Care and Specialty Pharmacy, 25(6), 646–651. https://doi.org/10.18553/jmcp.2019.25.6.646
dc.relation.referencesKohro, T., Yamazaki, T., Sato, H., Harada, K., Ohe, K., Komuro, I., & Nagai, R. (2013). Trends in Antidiabetic Prescription Patterns in Japan Impact of the Introduction of Dipeptidyl Peptidase-4 Inhibitors. International Heart Journal, 54(2), 93–97. https://doi.org/10.1536/ihj.54.93
dc.relation.referencesKunjathaya, P., Ramaswami, P. K., Krishnamurthy, A. N., & Bhat, N. (2013). Acute necrotizing pancreatitis associated with vildagliptin. JOP : Journal of the pancreas, 14(1), 81–84. https://doi.org/10.6092/1590-8577/1203
dc.relation.referencesLehrke, M., Leiter, L. A., Hehnke, U., Thiemann, S., Bhandari, A., Meinicke, T., & Johansen, O. E. (2016). Safety and efficacy of linagliptin in patients with type 2 diabetes mellitus and coronary artery disease: Analysis of pooled events from 19 clinical trials. Journal of Diabetes and its Complications, 30(7), 1378–1384. https://doi.org/10.1016/j.jdiacomp.2016.06.015
dc.relation.referencesLipska, K. J., Yao, X., Herrin, J., McCoy, R. G., Ross, J. S., Steinman, M. A., … Shah, N. D. (2017). Trends in drug utilization, glycemic control, and rates of severe hypoglycemia, 2006-2013. Diabetes Care, 40(4), 468–475. https://doi.org/10.2337/dc16-0985
dc.relation.referencesLønborg, J., Vejlstrup, N., Kelbæk, H., Bøtker, H. E., Kim, W. Y., Mathiasen, A. B., … Engstrøm, T. (2012). Exenatide reduces reperfusion injury in patients with ST-segment elevation myocardial infarction. European Heart Journal, 33(12), 1491–1499. https://doi.org/10.1093/eurheartj/ehr309
dc.relation.referencesLópez-Gonzales, G. K. (2018). Análisis retrospectivo de los eventos adversos de productos que contienen como principio activo insulina con registro sanitario en Colombia. Universidad Nacional de Colombia.
dc.relation.referencesMachado, J. E., Moncada, J. C., & Mesa, G. (2007). Patrones de prescripción de antidiabéticos en un grupo de pacientes colombianos. Revista Panamericana de Salud Pública, 22(2), 124–131. https://doi.org/10.1590/s1020-49892008000300005
dc.relation.referencesMachado, J., & Moncada, J. (2006). Reacciones Adversas Medicamentosas en Pacientes que consultaron a Instituciones Prestadoras de Servicios en Pereira, Colombia. Revista de Salud Pública, 8(2), 200–208. https://doi.org/10.1590/S0124-00642006000200008
dc.relation.referencesMarso, S. P., Bain, S. C., Consoli, A., Eliaschewitz, F. G., Jódar, E., Leiter, L. A., … Vilsbøll, T. (2016). Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. New England Journal of Medicine, 375(19), 1834–1844. https://doi.org/10.1056/NEJMoa1607141
dc.relation.referencesMarso, S. P., Daniels, G. H., Brown-Frandsen, K., Kristensen, P., Mann, J. F. E., Nauck, M. A., … Buse, J. B. (2016). Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes. New England Journal of Medicine, 375(4), 311–322. https://doi.org/10.1056/NEJMoa1603827
dc.relation.referencesMinisterio de Protección Social. Resolución 1403. , 1 § (2007).
dc.relation.referencesMinisterio de Salud. Decreto 677. , 1 § (1995).
dc.relation.referencesMinisterio de Salud y Protección social. (1993). Resolución N° 008430.
dc.relation.referencesMinisterio de Salud y Protección social. (2019). SISPRO (Sistema Integrado de la Información de la Protección Social). Recuperado el 20 de septiembre de 2019, de https://www.sispro.gov.co/Pages/Home.aspxhttps://www.sispro.gov.co/Pages/Home.aspx
dc.relation.referencesMinisterio de Salud y Protección Social. (2016). Guía de práctica clínica para el diagnóstico, tratamiento y seguimiento de la diabetes mellitus tipo 2 en la población mayor de 18 años. Guía para profesionales de la salud. Recuperado de http://gpc.minsalud.gov.co/gpc_sites/Repositorio/Conv_637/GPC_diabetes/Guia_Diabetes_Profesionales_Tipo_2.pdf
dc.relation.referencesMonami, M., Iacomelli, I., Marchionni, N., & Mannucci, E. (2010). Dipeptydil peptidase-4 inhibitors in type 2 diabetes: A meta-analysis of randomized clinical trials. Nutrition, Metabolism and Cardiovascular Diseases, 20(4), 224–235. https://doi.org/10.1016/j.numecd.2009.03.015
dc.relation.referencesMontilla, S., Marchesini, G., Sammarco, A., Trotta, M. P., Siviero, P. D., Tomino, C., … Roncadori, A. (2014). Drug utilization, safety, and effectiveness of exenatide, sitagliptin, and vildagliptin for type 2 diabetes in the real world: Data from the Italian AIFA Anti-diabetics Monitoring Registry. Nutrition, Metabolism and Cardiovascular Diseases, 24(12), 1346–1353. https://doi.org/10.1016/j.numecd.2014.07.014
dc.relation.referencesNakata, H., Sugitani, S., Yamaji, S., Otsu, S., Higashi, Y., Ohtomo, Y., & Inoue, G. (2012). Pancreatitis with Pancreatic Tail Swelling Associated with Incretin-based Therapies Detected Radiologically in Two Cases of Diabetic Patients with End-Stage Renal Disease. Internal Medicine, 51(21), 3045–3049. https://doi.org/10.2169/internalmedicine.51.7876
dc.relation.referencesNeal, B., Perkovic, V., Mahaffey, K. W., De Zeeuw, D., Fulcher, G., Erondu, N., … Matthews, D. R. (2017). Canagliflozin and cardiovascular and renal events in type 2 diabetes. New England Journal of Medicine, 377(7), 644–657. https://doi.org/10.1056/NEJMoa1611925
dc.relation.referencesPapale, Rosa María; Schiaffino, Santiago; García-Darderes, M. G. (2018). Manual de Buenas Prácticas de Farmacovigilancia (Ediciones; Wiley, ).
dc.relation.referencesPelletier, R., Ng, K., Alkabbani, W., Labib, Y., Mourad, N., & Gamble, J. (2020). The association of sodium‐glucose cotransporter 2 inhibitors with cancer: An overview of quantitative systematic reviews. Endocrinology, Diabetes & Metabolism, 3(3). https://doi.org/10.1002/edm2.145
dc.relation.referencesPfeffer, M. A., Claggett, B., Diaz, R., Dickstein, K., Gerstein, H. C., Køber, L. V., … Tardif, J.-C. (2015). Lixisenatide in Patients with Type 2 Diabetes and Acute Coronary Syndrome. New England Journal of Medicine, 373(23), 2247–2257. https://doi.org/10.1056/NEJMoa1509225
dc.relation.referencesPino Marín, D., Madrigal Cadavid, J., Ceballos, M., Cano, A., & Amariles, P. (2018). Resultados de la implementación del reporte de sospecha de reacciones adversas a medicamentos por pacientes: revisión estructurada. Revista de la Universidad Industrial de Santander. Salud, 50(2), 136–142. https://doi.org/10.18273/revsal.v50n2-2018005
dc.relation.referencesPRAC EMA. (2016). SGLT2 inhibitors. Recuperado de Referrals website: https://www.ema.europa.eu/en/medicines/human/referrals/sglt2-inhibitors
dc.relation.referencesPRAC EMA. (2017). SGLT2 inhibitors (previously canagliflozin). Recuperado de Referrals website: https://www.ema.europa.eu/en/medicines/human/referrals/sglt2-inhibitors-previously-canagliflozin
dc.relation.referencesQuaglia, N. B., Nuñez, M. H., & Marzi, M. M. (2012). Patrones de prescripción de medicamentos e indicadores demográficos en una población diabética de Argentina. Farmacia Hospitalaria, 36(2), 92–96. https://doi.org/10.1016/j.farma.2011.02.008
dc.relation.referencesRaschi, E., Poluzzi, E., Koci, A., Antonazzo, I. C., Marchesini, G., & De Ponti, F. (2016). Dipeptidyl peptidase-4 inhibitors and heart failure: Analysis of spontaneous reports submitted to the FDA Adverse Event Reporting System. Nutrition, Metabolism and Cardiovascular Diseases, 26(5), 380–386. https://doi.org/10.1016/j.numecd.2016.02.006
dc.relation.referencesRaschi, E., Poluzzi, E., Salvo, F., Pariente, A., De Ponti, F., Marchesini, G., & Moretti, U. (2018). Pharmacovigilance of sodium-glucose co-transporter-2 inhibitors: What a clinician should know on disproportionality analysis of spontaneous reporting systems. Nutrition, Metabolism and Cardiovascular Diseases, 28(6), 533–542. https://doi.org/10.1016/j.numecd.2018.02.014
dc.relation.referencesRed de puntos focales de farmacovigilancia para las Américas. (2016). Señales en farmacovigilancia para las Américas.
dc.relation.referencesRoos, S. T., Timmers, L., Biesbroek, P. S., Nijveldt, R., Kamp, O., van Rossum, A. C., … Appelman, Y. (2016). No benefit of additional treatment with exenatide in patients with an acute myocardial infarction. International Journal of Cardiology, 220, 809–814. https://doi.org/10.1016/j.ijcard.2016.06.283
dc.relation.referencesSamardžić, I., & Bačić-Vrca, V. (2015). Incidence of potential drug-drug interactions with antidiabetic drugs. Pharmazie, 70, 410–415. https://doi.org/10.1691/ph.2015.4777
dc.relation.referencesSaraogi, R., Mallik, R., & Ghosh, S. (2012). Mild acute pancreatitis with vildagliptin use. Indian journal of endocrinology and metabolism, 16(Suppl 2), S480-2. https://doi.org/10.4103/2230-8210.104138
dc.relation.referencesSchmidt, L. J., Habacher, W., Augustin, T., Krahulec, E., & Semlitsch, T. (2014). A systematic review and meta-analysis of the efficacy of lixisenatide in the treatment of patients with type 2 diabetes. Diabetes, Obesity and Metabolism, 16(9), 769–779. https://doi.org/10.1111/dom.12269
dc.relation.referencesScholte, M., Timmers, L., Bernink, F. J., Denham, R. N., Beek, A. M., Kamp, O., … Appelman, Y. (2011). Effect of additional treatment with EXenatide in patients with an Acute Myocardial Infarction (EXAMI): study protocol for a randomized controlled trial. Trials, 12(1), 240. https://doi.org/10.1186/1745-6215-12-240
dc.relation.referencesScirica, B. M., Bhatt, D. L., Braunwald, E., Steg, P. G., Davidson, J., Hirshberg, B., … Raz, I. (2013). Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. New England Journal of Medicine, 369(14), 1317–1326. https://doi.org/10.1056/NEJMoa1307684
dc.relation.referencesSfairopoulos, D., Liatis, S., Tigas, S., & Liberopoulos, E. (2018). Clinical pharmacology of glucagon-like peptide-1 receptor agonists. Hormones, 17(3), 333–350. https://doi.org/10.1007/s42000-018-0038-0
dc.relation.referencesSingh, S. (2014). Type 2 Diabetes Pharmacoepidemiology Update 2014: Safety Versus Efficacy. Current Diabetes Reports, 14(12). https://doi.org/10.1007/s11892-014-0563-4
dc.relation.referencesSterrett, J. J., Bragg, S., & Weart, C. W. (2016). Type 2 Diabetes Medication Review. American Journal of the Medical Sciences, 351(4), 342–355. https://doi.org/10.1016/j.amjms.2016.01.019
dc.relation.referencesTabesh, M., Magliano, D. J., Tanamas, S. K., Surmont, F., Bahendeka, S., Chiang, C. E., … Shaw, J. E. (2019). Diabetes management and treatment approaches outside of North America and West Europe in 2006 and 2015. Acta Diabetologica, 56(8), 889–897. https://doi.org/10.1007/s00592-018-01284-4
dc.relation.referencesTang, H., Dai, Q., Shi, W., Zhai, S., Song, Y., & Han, J. (2017). SGLT2 inhibitors and risk of cancer in type 2 diabetes: a systematic review and meta-analysis of randomised controlled trials. Diabetologia, 60(10), 1862–1872. https://doi.org/10.1007/s00125-017-4370-8
dc.relation.referencesThrasher, J. (2017). Pharmacologic Management of Type 2 Diabetes Mellitus: Available Therapies. American Journal of Cardiology, 120(1), S4–S16. https://doi.org/10.1016/j.amjcard.2017.05.009
dc.relation.referencesTorres, D. R., Portilla, A., Machado-Duque, M. E., & Machado-Alba, J. E. (2017). Trends in the use and cost of human and analogue insulins in a Colombian population, 2011–2015. Public Health, 153, 64–69. https://doi.org/10.1016/j.puhe.2017.08.011
dc.relation.referencesTurnbull, F. M., Abraira, C., Anderson, R. J., Byington, R. P., Chalmers, J. P., Duckworth, W. C., … Woodward, M. (2009). Intensive glucose control and macrovascular outcomes in type 2 diabetes. Diabetologia, 52(11), 2288–2298. https://doi.org/10.1007/s00125-009-1470-0
dc.relation.referencesVasilakou, D., Karagiannis, T., Athanasiadou, E., Mainou, M., Liakos, A., Bekiari, E., … Tsapas, A. (2013). Sodium–Glucose Cotransporter 2 Inhibitors for Type 2 Diabetes. Annals of Internal Medicine, 159(4), 262. https://doi.org/10.7326/0003-4819-159-4-201308200-00007
dc.relation.referencesWHO. (2016). Global report on diabetes (WHO press, Ed.). Recuperado de http://www.who.int
dc.relation.referencesWHO Collaborating Centre for Drug Statistics Methodology. (2019). ATC/DDD Index 2019. Recuperado el 20 de septiembre de 2019, de https://www.whocc.no/atc_ddd_index/
dc.relation.referencesWilliams-Herman, D., Engel, S. S., Round, E., Johnson, J., Golm, G. T., Guo, H., … Goldstein, B. J. (2010). Safety and tolerability of sitagliptin in clinical studies: a pooled analysis of data from 10,246 patients with type 2 diabetes. BMC Endocrine Disorders, 10(1), 7. https://doi.org/10.1186/1472-6823-10-7
dc.relation.referencesWorld Health Organization (WHO) International Working Group for Drug Statistics Methodology. (2003). Introduction to Drug Utilization Research. En World Heath Organization. Oslo, Noruega: World Health Organization.
dc.relation.referencesYaribeygi, H., Sathyapalan, T., & Sahebkar, A. (2019). Molecular mechanisms by which GLP-1 RA and DPP-4i induce insulin sensitivity. Life Sciences, 234(August), 116776. https://doi.org/10.1016/j.lfs.2019.116776
dc.relation.referencesYehya, A., & Sadhu, A. R. (2018). New Therapeutic Strategies for Type 2 Diabetes CME. Methodist DeBakey cardiovascular journal, 14(4), 281–288. https://doi.org/10.14797/mdcj-14-4-281
dc.relation.referencesZaccardi F, Htike ZZ, Webb DR, Khunti K, D. M. (2016). Benefits and Harms of OnceWeekly Glucagon-like Peptide-1 Receptor Agonist Treatments: A Systematic Review and Network Meta-analysis. Ann Intern Med, 164, 102–113.
dc.relation.referencesZurro, Martin A. Cano Perez, J. F. (1998). Atencion primaria: conceptos organización y practica (4a ed.). Elsevier.
dc.rights.accessrightsinfo:eu-repo/semantics/openAccess
dc.subject.proposalAdverse events
dc.subject.proposalEventos adversos
dc.subject.proposalDrug consumption data
dc.subject.proposalDatos de consumo de medicamentos
dc.subject.proposalGLP-1 receptor analogues
dc.subject.proposalInhibidores de dipeptidil peptidasa
dc.subject.proposalDPP-4 inhibitors
dc.subject.proposalAnálogos del receptor GLP-1
dc.subject.proposalInhibidores del cotransportador SGLT2
dc.subject.proposalSGLT2 cotransporter inhibitors
dc.subject.proposalDesproporcionalidad
dc.subject.proposalDisproportionality
dc.subject.proposalFarmacovigilancia
dc.subject.proposalPharmacovigilance
dc.type.coarhttp://purl.org/coar/resource_type/c_1843
dc.type.coarversionhttp://purl.org/coar/version/c_ab4af688f83e57aa
dc.type.contentText
oaire.accessrightshttp://purl.org/coar/access_right/c_abf2


Archivos en el documento

Thumbnail
Nombre:
1024555898.2020.pdf
Tamaño:
1.299Mb
Formato:
PDF
Descargar
Thumbnail
Nombre:
license_rdf
Tamaño:
701bytes
Formato:
application/rdf+xml
Descargar

Este documento aparece en la(s) siguiente(s) colección(ones)

Mostrar el registro sencillo del documento

Atribución-NoComercial 4.0 InternacionalEsta obra está bajo licencia internacional Creative Commons Reconocimiento-NoComercial 4.0.Este documento ha sido depositado por parte de el(los) autor(es) bajo la siguiente constancia de depósito